BPC-157 vials vs capsules: which form should you buy?

BPC-157 vials vs capsules: the short answer

If you are buying BPC-157 for laboratory research, buy a vial. The vial form, a lyophilized powder sealed under a stopper, is what the synthetic peptide is made as, what the peer-reviewed literature has used, and what every research supplier in our BPC-157 vendor comparison except one sells. Astral sells BPC-157 as a 10 mg vial at $47.99, which is $4.80 per mg, and sells no capsules or oral forms at all.

Capsules and tablets exist because the peptide has a reputation in the animal literature for surviving gastric juice. That reputation is real as far as it goes, and this page explains it, but it has never been tested in a published human pharmacokinetic study, and the two oral products in our comparison are a different thing from the vial a study would specify.

See BPC-157 vials at Astral →

What is a BPC-157 vial?

A BPC-157 vial is a small glass vial containing synthetic BPC-157 as a lyophilized, or freeze-dried, powder, sealed with a rubber stopper and a crimped cap. The amount is stated as a weight of peptide, 5, 10 or 15 mg among the vendors we compared, and a laboratory adds bacteriostatic water to reconstitute it. Astral’s product page describes its vial as “Freeze-dried powder sealed in a vial, with no liquid inside.”

The peptide itself is a pentadecapeptide, fifteen amino acids in the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight about 1,419.5 daltons, CAS number 137525-51-0, made by solid-phase synthesis. Astral’s listing prints the name, the subtitle “Pentadecapeptide”, the synonym PL-14736 and the CAS number.

What are BPC-157 capsules?

A BPC-157 capsule or tablet is an oral product in which a small amount of the peptide, typically a fraction of a milligram, is formed with excipients into a solid unit. The amount is stated per unit or per bottle. In our comparison SwissChems sells 60 capsules holding 30 mg of BPC-157 in total, and American Peptides sells 30 tablets holding 15 mg in total, described on its page as supplied in solid form with no reconstitution step and no diluent.

Two things follow from the format. The contents cannot be reconstituted at a concentration a study chooses, because the peptide is locked into a fixed unit with excipients. And the identity and quantity of the peptide are harder to confirm than in a vial, where a single weight describes the whole content.

Which form has the published research used?

Vials. The BPC-157 literature, which runs to decades of animal studies and a handful of small human reports, has used synthetic BPC-157 prepared from powder. The 2025 literature and patent review in Pharmaceuticals describes the compound and the routes studied in animals; a 2026 review in Pharmaceutics frames it as an investigational peptide whose formulation strategies are still being worked out, with “no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial.” Neither describes a capsule product.

On the human side there is almost nothing for any route. The Pharmaceutics review counts “fewer than 30 subjects across three uncontrolled pilot studies”, and a 2026 systematic review in Acta Orthopaedica Belgica found three studies with thirty participants, judged “of poor methodological quality”, with certainty of evidence rated very low. The registered trials on ClinicalTrials.gov, including the phase 2 study NCT07437547 recruiting as of November 12, 2026, have posted no results. None of that is a capsule study, and none of it supports a vendor’s claim about what an oral product does in people.

Is oral BPC-157 stable? What the research says

This is the honest basis for the capsule products, so it deserves a fair account. BPC-157 was originally described as a pentadecapeptide isolated from human gastric juice, and the 2025 Pharmaceuticals review says its structural composition “renders this peptide stable in water and gastric juice”. The 2026 Pharmaceutics review goes further on routes, saying the peptide “exhibits unusual stability in gastric juice and demonstrates activity via oral, parenteral, and topical routes” in the literature it surveys, and then adds the sentence that matters for a buyer: “its human pharmacokinetic profile remains critically undercharacterized”.

So the animal and in-vitro record says the molecule tolerates gastric conditions, and the human record says nothing yet about how any oral product behaves in people. A capsule vendor is selling on the first half of that sentence. A research buyer should read the second half, and note that a capsule’s stability on the shelf, as a manufactured product with excipients, is a separate question from the peptide’s stability in gastric juice.

How are vials and capsules stored and handled?

A sealed vial is the easier of the two to store with confidence, because its behavior is documented. Astral’s page states that “Lyophilized peptides are stable at room temperature for many months” and that reconstituted peptide should be refrigerated and used within four to six weeks. Keep sealed vials dry and out of light, let a cold vial reach room temperature before opening it, and reconstitute with bacteriostatic water, which Astral sells as Reconstitution Solution (Astral’s bacteriostatic water: a 30 mL Hospira vial) at $37.99. Astral’s peptide storage guide and reconstitution guide cover the handling, and Astral’s peptide calculator does the reconstitution math.

A capsule product’s shelf life depends on its formulation, which only its maker can document. A vial’s contents are a single identified peptide at a stated weight, which is why its storage guidance can be stated simply and why a laboratory can verify what it has.

Why lyophilized vials are the standard research form

• Identity. The vial contains one peptide. The name, CAS number and sequence on the label describe the whole contents.
• Quantity. The label states a weight of peptide, and a reconstituted vial yields a known concentration chosen by the laboratory.
• Stability. The lyophilized form is stable at room temperature for many months sealed, which is why vendors can ship it without cold chain.
• Documentation. A research supplier can publish a certificate of analysis for a lot of powder; Astral does for its BPC-157. A capsule’s fill is harder to analyze.
• Continuity with the literature. A study that used synthetic BPC-157 reconstituted from powder can be followed with a vial, not with a capsule.

Who sells BPC-157 capsules, and what do they cost?

Prices as listed on each vendor’s site on November 12, 2026. Per-mg figures for the oral products are per listed milligram of content and are not comparable with the vial figures, which is why the table keeps them in separate rows.

The oral products are cheaper per listed milligram than any vial, and that is the whole of their case; it is not a like-for-like saving. A buyer paying for 30 mg of peptide in capsules is paying for an oral product with no human data, a fixed format, and an identity that is harder to verify, where a buyer paying $47.99 for Astral’s 10 mg vial gets the form the research used, with the peptide’s identity and weight on the label. SwissChems showed no vial price on November 12, 2026.

Where to buy BPC-157 vials

From a research supplier that sells the lyophilized form, names the molecule, and keeps its page to research use. Astral is our pick: its peptides are synthesized and manufactured in the United States, it ships from its own New York inventory, its 10 mg vial is the lowest standard price per mg of any vial in our comparison, and its product page says plainly that the vial holds freeze-dried powder for laboratory research and that the compound has no FDA approval. On those points it is in a class of its own. A lab that also needs TB-500 can buy it from the same inventory, or buy both peptides in one vial as Wolverine (Astral’s BPC-157 + TB-500 blend); our BPC-157 vs Wolverine page compares the two. For the regulatory background, see whether BPC-157 is legal to buy.

Buy BPC-157 vials at Astral →